A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group,

Recruiting

18-100 years

All

Phase 3

20000 participants needed

1 Location

Brief description of study

This is a study comparing the efficacy and safety of milvexian to apixaban for the prevention of stroke and non-CNS systemic embolism in participants with atrial fibrillation.

Detailed description of study

Participants will be assigned in a 1:1 ratio to receive either milvexian or apixaban. The total study duration from first patient in (FPI) to last patient out (LPO) is approximately 4 years.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Atrial Fibrillation
Age: Between 18 Years - 100 Years
Gender: All

Inclusion

Atrial fibrillation or flutter, and eligible to receive anticoagulation therapy
One or more of the ff risk factors ( age> 65y/o, hypertension, diabetes, coronary artery disease, PAD, heart failure)

Exclusion

Prior disabling stroke
Current active liver disease
Require dialysis
History of any significant drug allergy

Updated on 16 Sep 2024. Study ID: 853443

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).